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Cytomegalovirus infection-enhanced chronic kidney allograft rejection
is linked with intercellular adhesion molecule-i expression. In human
kidney allografts, association of acute rejection and glomerulopathy with
cytomegalovirus (CMV) infection has been demonstrated. To investigate
the effect of CMV infection on the development of experimental chronic
kidney allograft rejection, heterotopic kidney allografts from DA (Ag-B4,
RT1aJ) rat donors to WF (Ag-B2, RT1) rat recipients were used. The
animals received cyclosporine A (CsA) 5 mg/kg/day s.c. either for 1 or 12
weeks. Two groups of recipients were infected with iO plaque-forming
units of rat CMV (RCMV) and two other groups were left noninfected
and used as controls. The grafts were removed 12 weeks after transplan-
tation for histology and immunohistochemistry. RCMV infection signifi-
cantly enhanced the development of chronic kidney allograft rejection in
rats on continuous CsA the intensity of interstitial inflammation (P <
0.025), particularly the degree of pyroninophilic cells in the inflammatory
infiltrate (P < 0.025), the glomerular mesangial matrix increase (P < 0.05)
and capillary basement membrane thickening (P < 0.01), the extent of
endothelial cell swelling (P < 0.025) and intimal proliferation (P < 0.025)
in the graft vasculature, and the extent of tubular epithelial atrophy (P <
0.025). Chronic allograft damage index (CADI) was significantly increased
to 4.3 0.8 in RCMV-infected allografts, compared to 0.8 0.4 in
noninfected (P < 0.02). In addition, RCMV infection significantly in-
creased the number of acute rejection episodes (serum creatinine > 200
jsmol/liter, P < 0.05) and almost doubled the end-stage serum creatinine.
RCMV infection significantly increased ICAM-1 expression on the vascu-
lar endothelium (P < 0.05) and tubular epithelial cells (P < 0.01), and was
linked with enhanced interstitial, glomerular, and tubular inflammation. In
80% of allografts on continuous CsA, RCMV antigens could be observed
in sporadic inflammatory cells one week after infection and in tubular
epithelial cells at 12 weeks. In heavily inflamed allografts where the CsA
treatment was discontinued at one week, enhancement of RCMV infec-
tion on the histological changes attributable to chronic kidney allograft
rejection could not be demonstrated. Our results show that during CsA
immunosuppression, RCMV infection enhances chronic kidney allograft
rejection associated with increased interstitial inflammation as well as
vascular endothelial and tubular epithelial ICAM-1 expression.
Chronic rejection, characterized by interstitial fibrosis, glomer-
uloscierosis, tubular atrophy and arterial narrowing, is the major
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reason for the loss of renal allografts after the first post-transplant
year [1]. Although the pathogenetic mechanism of chronic rejec-
tion is poorly understood, it has been suggested that chronic
rejection may be a result of the production of cytokines and
growth factors [2] by different cell types, leading to a proliferative
remodeling of graft vessels along with structural changes in the
parenchyma, and gradual deterioration of graft function. Acute
rejection is probably the most important single risk factor for
chronic rejection [3, 4]. In addition, at least the following param-
eters contribute to the development of this disorder: histoincom-
patibility, preservation time, donor and recipient age, hyperlipid-
emia, inadequate immunosuppression, and renal mass [5—8].
Previous studies have demonstrated that cytomegalovirus (CMV)
infection is a significant risk factor for the development of graft
failure and death after renal transplantation [91. Reinke and
co-workers recently observed that asymptomatic CMV infection is
directly linked to histologically proven renal allograft injury, and
antiviral therapy with ganciclovir resulted in improved graft
function in patients with CMV-associated late acute rejection
[10].
This study examined the accelerating effect of rat CMV
(RCMV) infection on the development of chronic kidney allograft
rejection, by applying heterotopic rat kidney allografts immuno-
suppressed with cyclosporine A (C5A) for either 1 or 12 weeks.
The accelerating effect of RCMV infection was found to be
associated with a significantly increased interstitial inflammatory
response of helper T cells, cytotoxic T cells, activated macro-
phages as well as of vascular endothelial and tubular epithelial
intercellular adhesion molecule-i (ICAM-1) expression.
Methods
Experimental design
To investigate the effect of CMV infection on the development
of chronic kidney allograft rejection, heterotopic kidney allografts
from DA (Ag-B4, RTlal) donor to WF (Ag-B2, RT1U) recipient
rats were used. The rats received cyclosporine A (C5A) 5 mg/kg!
day s.c. either for I or 12 weeks as described in our previous study
[8], where kidney allografts in the 1-week group developed
chronic rejection three months post-transplantation, whereas
grafts in the 12-week group remained intact. Two groups of
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recipients were infected with i0 plaque-forming units of rat
CMV (RCMV) nine days after transplantation, and two other
groups were left noninfected and used as controls. We have
previously demonstrated that syngenic DA-DA kidney grafts
under CsA do not develop any histopathological changes attrib-
utable to chronic rejection [11], and thus syngenic controls were
not performed.
At seven days after transplantation, left nephrectomy was
performed to remove recipient's own kidney. The rats were
monitored twice a week for serum creatinine. The diagnosis of
acute rejection was made if a rise in serum creatinine > 200
mmol/liter was observed and if other specific reasons were
excluded. On such occasions, additional CsA was given s.c. at a
dose of 5 mg/kg of body weight during the period when serum
creatinine stayed at > 200 mmollliter to counteract acute rejec-
tion. The first rejection episode was always verified by core needle
biopsy taken with a Biopty instrument (Radioplast, Uppsala,
Sweden) with a 18 G Biopty-Cut needle. The needle was placed
parallel to the long axis of the graft and two cores of tissue were
obtained. No grafts were lost to the biopsy.
The grafts were removed 12 weeks after transplantation for
histology and immunohistochemistry. At graft removal, biopsies
from salivary glands, liver, and spleen were taken for quantative
plaque assay to confirm a generalized RCMV infection in the
recipient. The presence of RCMV early and late antigens in
kidney allografts were demonstrated by the immunoperoxidase
technique.
Experimental animals
Inbred male DA (AG-B4, RT1') and WF (AG-B2, RT1") rat
strains were used as donors and recipients, respectively. The
animals were purchased from Laboratory Animal Center, Univer-
sity of Helsinki, Helsinki, Finland. They were 10 to 12 weeks of
age and weighed 250 to 300 g. The rats were fed with regular rat
food (altromin; Standard Dicet, Chr. Petersen A'S, Ringsted,
Denmark) and tap water ad libitum. The infected and noninfected
rats were kept in separate colonies with otherwise similar diet and
conditions. The animals received humane care in compliance with
The Principles of Laboratory Animal Care and The Guide for the
Care and Use of Laboratoty Animals, prepared and formulated by
the Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH Publication No. 86-23,
revised 1985).
Transplantations
Transplantations were performed from the DA to the WF rat
strain using a modified microvascular surgical technique of Fisher
and Lee [12]. The donor kidney was transplanted heterotopically
utilizing end-to-side aortic and vena caval anastomosis under
intraperitoneal chloral hydrate anaesthesia. Ureter anastomosis
was performed end-to-end close to the renal pelvis. The recipi-
ent's own right kidney was removed during transplantation and
left nephrectomy was delayed for seven days to allow recovery
from acute tubular necrosis. Buprenorphinum (Temgesic; Reckitt
& Colman, Hull, UK) was used for postoperative pain relief. Total
perioperative ischemia time was standardized between 25 and 30
minutes, beginning with exanguination and cold perfusion of the
graft and ending with revascularization of the graft.
Definition of chronic rejection
In a consensus conference on chronic rejection, the Fourth
Alexis Carrel Conference in Kiruna, Sweden [13], chronic renal
allograft rejection was defined as the "gradual deterioration in
graft function in the absence of any other disease and necessary
graft histology to confirm the diagnosis." In this study we used
these criteria applied to the rat. In addition to descriptive
histopathologic diagnosis of chronic rejection, quantitative biopsy
histology was used to evaluate the intensity of histological
changes.
Quantitation of histopathology and the "Chronic Allograft Damage
Index"
The grafts were harvested at 12 weeks after transplantation,
bisected horizontally and fixed in 10% buffered formalin. The
specimens were examined histologically following sectioning and
staining with hematoxylin-eosin, Masson's trichrome, periodic
acid-Schiff and methyl-green-pyronin. To quantitate histological
changes in renal allografts, we scored 30 different parameters
blindly from 0 to 3 (no changes-severe changes) and computerized
the data. The "Chronic Allograft Damage Index" (CADI; sum of
6 parameters: interstitial inflammation and fibrosis, glomerular
mesangial matrix increase and sclerosis, vascular intimal prolifer-
ation and tubular atrophy) expresses the intensity of chronic
changes in the transplant as a single number [8].
AUCC, calculation
Area under the postoperative serum creatinine versus time
curve (AUCcre) > 100 mmol/liter of serum creatinine was calcu-
lated using Microsoft Excel (Microsoft Corporation, Redmond,
WA, USA) software program [8].
RCMV infection
Rat CMV infection in kidney allograft recipients was estab-
lished by inoculating i.p. io PFU of Maastricht strain RCMV [14,
15] nine days after transplantation (2 days after the recipient's
own kidney was removed). The RCMV pooi used consisted of
tissue culture-derived RCMV diluted in 1 ml PBS before inocu-
lation. RCMV was passaged by infecting rat embryo fibroblasts
from 17-day-old DA rat embryos. The cells were cultured in flasks
containing Modified Eagle's minimal essential medium (Flow
Laboratories, Irvine, UK) supplemented with 200 mi L-glu-
tamine (Northumbria Biologicals LTD, Cramlington, UK), 10,000
lU/mi penicillin/1,000 g/ml streptomycin solution (Gibco Ltd.,
Paisley, UK), and 2% fetal calf serum (Gibco) according to
standard viral culture techniques [16]. The stocks of virus were
stored at —70°C until used.
Potency testing of RCMV pool
Quantitations of infectious virus were done by plaque assays
using a modification of the method of Wentworth and French
[17]. Confluent DA rat embryo fibroblast monolayers were in-
fected with an appropriate virus dilution and incubated in a 5%
CO2 incubator at 37°C for 90 minutes. Following incubation the
infected cells were overlaid with 1 ml D-minimal essential me-
dium (Biological Industries, Kibbutz Beth, Haemek, Israel) with a
final concentration of 0.25% agar (Bacto-Agar, Difco, Detroit,
MI, USA). After incubation for seven days, the cells were fixed
with 10% formalin overnight. Following fixation, the solid base
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Table 1. Monoclonal antibodies used to characterize the structure of inflammation and immune activation in the allografts
Antibody Specificity Manufacturer
W3/25 Helper T cells
CD 4 equivalent
Sera Lab, Sussex, England
0X8 T cells (non-helper subset) Sera Lab
(Lyt2/Lyt3) CD 8 equivalent
ED 1 Macrophages, monocytes Serotec
ED 2 Macrophages, dendritic cells Serotec
ED 3 Macrophages Serotec
3.2.3 Natural killer (NK) cells Gift from Dr. W.H. Chambers, Pittsburgh Cancer Institute,
Pittsburgh, PA
CD 25 Interleukin 2 receptor on activated T cells Gift from Dr. J. Kupiec-Weglinski, Harvard Medical School,
Boston, MA
OX 6 MHC class II common determinant on activated T cells Sera Lab
1A29 (CD 54) ICAM-1 on leukocytes and endothelial cells Seikagaku Co., Tokyo, Japan
SF10 (CD 106) VCAM-1 on endothelial cells Gift from Dr. Roy Lobb, Biogen, Cambridge, MA
layer was removed and the cell monolayers were stained with 1%
methylene blue, and the plaques were counted by light micros-
copy.
Quantitative plaque assay
At graft removal, tissue biopsies from salivary glands, liver and
spleen were obtained aseptically in minimal essential medium
containing 2% fetal calf serum, and stored at —70°C until
quantitation of infectious RCMV was done by plaque assays [17].
For this purpose, tenfold dilutions of 10% organ homogenates
(wt/vol) were inoculated on confluent rat embryo fibroblast
monolayers. After incubation for seven days, the number of
plaques was monitored microscopically following methylene blue
staining.
Imrnunohistochemistiy
Table I lists the monoclonal antibodies used to evaluate the
structure of inflammation and immune activation of infiltrating
leukocytes in the grafts. A piece of allograft was taken in optimal
cutting temperature embedding (O.C.T., Tissue-Tek; Miles Inc.,
Elkhart, IN, USA), snap-frozen in liquid nitrogen, and stored at
—70°C. Frozen sections were air dried onto poly-D-lysine-coated
slides, fixed in acetone at —20°C for 20 minutes and stored at
—20°C until used. Before immunostaining, the slides were refixed
with chloroform, and then air dried. Four-micron thick cross
sections were incubated with monoclonal antibodies using a
three-layer indirect immunoperoxidase technique [18]. The pri-
mary antibodies were used at a dilution of 1:100 in Tris with 1%
BSA. Following a 30-minute incubation at room temperature, the
sections were washed in Tris-buffer and incubated for another 30
minutes with peroxidase-conjugated rabbit anti-mouse Ig at a
dilution of 1:10 in Tris-buffer with 50% rat normal sera (Dako-
immunoglobulins AJS, Copenhagen, Denmark). After washing in
Tris-buffer, the sections were incubated with peroxidase-conju-
gated goat anti-rabbit Ig at a dilution of 1:10 in Tris-buffer with
50% rat normal sera (Caltag Lab., San Francisco, CA, USA). The
reaction was revealed by chromogen 3-amino-9-ethylcarbazole
containing hydrogen peroxidase. The specimens were counter-
stained with hematoxylin and coverslips aquamounted (Aqua-
mount; BDH Ltd., Poole, UK). No difference was observed
whether incubation with non-immune rabbit sera for nonspecific
reaction or methanol containing 1% H202 for endogenous per-
oxidase was done before staining. For controls the primary
antibody was left out, but otherwise the staining was performed in
a similar fashion, and the controls did not show any unspecific
immunoreactivity.
Quantitation of immunohistochemistiy
The structure of inflammation and the level of immune activa-
tion were assessed from inflammatory cells. The analysis was done
semiquantitatively by scoring the staining from 0 to 3 (0 = no
visible staining, 1 = few cells with faint staining, 2 = moderate
intensity with multifocal staining, 3 = intense diffuse staining of
cells analyzed).
Immunoperoxidase staining for the detection of early and late
RCMV antigens
For the detection of RCMV antigens, 4 m thick formalin-fixed
paraffin-embedded tissue sections of kidney allografts were
stained with a mixture of monoclonal antibodies against early
(monoclonal #8) and late (monoclonal #35) antigens of RCMV
[19, 20]. For controls, primary antibody was left out but otherwise
the staining procedure was performed in a similar fashion. These
controls did not show any nonspecific immunoreactivity.
The sections were applied onto Chromaluin (Merck 1036)-
coated slides, deparaffinized, and endogenous peroxidase was
blocked by methanol containing 0.6% H202. Before immuno-
staining, the sections were preincubated with 0.1% pepsin con-
taining 0.1 M HC1, washed, and preincubated with PBS containing
2% rat sera. A mixture of primary monoclonal antibodies was
diluted in PBS with 0.1% BSA and 0.1% Tween 20. A second
incubation was performed with biotinylated affinity-purified sheep
anti-mouse IgG antibodies (Amersham, Nederland B.V.) diluted
in PBS with 0.1% BSA and Tween 20. Thereafter, the tissue
sections were incubated with streptavidin-biotin horseradish per-
oxidase complex (Amersham) diluted in PBS with 0.1% BSA and
0.1% Tween 20. The reaction was revealed by chromogen 3,3'-
diaminobenzidine tetrahydrochloride (Serva 18865) with 0.5 M
Tris-HC1 and 0.1 M imidazole (Sigma 1-7125). The specimens were
counterstained with hematoxylin and coverslips aquamounted
with Entellan (Merck 7961).
Statistical analyses
All data are expressed as mean SEM. A nonparametric test
was chosen due to small sample sizes and inability to determine if
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Table 2. Effect of immunosuppression on the presence of infectious
RCMV in kidney allograft recipients 3 months after transplantation as
demonstrated by plaque assays
Number of rats
Group positive/tested rats Virus titer PFU/ml"
1 week CsA treatment
Liver/spleen 0/5 neg
Salivaiy glands 3/5 4.5 2.2 x io
12 weeks CsA treatment
Liver/spleen 0/5 neg
Salivary glands 4/5 7.0 2.0 X iO
The presence of infectious RCMV in organ biopsies of liver, spleen,
and salivaiy glands was demonstrated by plaque assays. Organs were
homogenized in Eagle's minimum essential medium with 2% fetal calf
serum, and 10-fold dilutions of 10% homogenates (wt/vol) were inocu-
lated on confluent rat embryo fibroblast monolayers. After incubation for
7 days, the plaques were monitored.bThe virus titer in plaque assays is expressed as plaque forming units
per ml (PFU/ml) of organ homogenates. Data are mean SEM.
P < 0.025 by Mann-Whitney U-test
the samples were normally distributed [21]. Statistical analysis of
differences in the results was performed between two groups with
similar immunosuppression with and without RCMV infection, as
this kind of analysis was assumed to be more relevant to this study
than comparison between all the groups. Therefore, the total
variation between the groups was analyzed by the nonparametric
Mann-Whitney U-test, Z corrected for ties (Statview 5l2; Brain-
Power Inc., Calabasas, CA, USA). Values of P < 0.05 were
regarded as statistically significant.
Results
RCMV infection in kidney allograft recipients
We have earlier described the natural history of RCMV
infection in the allograft recipient [22]. In brief, infected rats have
usually asymptomatic infection, unless they have not received
strong immunosuppression, like total body irradiation [23, 24].
Liver and spleen contain infectious RCMV 5 to seven days after
infection and are negative thereafter (acute systemic infection).
To the contrary, salivary glands are usually RCMV positive from
one to four months after infection (chronic infection). Later on,
no infectious RCMV can be detected from the host (latent
infection).
In this study, the infected rats did not show any clinical
symptoms of the disease. As demonstrated in Table 2, biopsies
taken from liver and spleen were negative in plaque assays at
three months in the 1- and 12-week CsA treatment groups. In
contrast, salivary glands, the preferential site of RCMV, con-
tained infectious RCMV in both groups. However, higher quan-
tities of infectious RCMV could be demonstrated from salivary
glands of the 12-week CsA treatment group as compared to the
1-week CsA treatment group.
RCMV infection in kidney allografts
In 4 of 5 (80%) of kidney allografts with 12-week CsA treat-
ment, sporadic inflammatory cells expressing RCMV early and
late antigens were detected one week after viral infection (16 days
after transplantation). No antigen expression occurred in RCMV-
infected kidney allografts with one week of CsA treatment. Four
weeks after infection, no RCMV antigen positive cells could be
detected in either group. At three months, RCMV early and late
antigen positive tubular epithelial cells could be found in 4 of 5
(80%) kidney allografts with the 12-week CsA treatment com-
pared to none with the 1-week CsA treatment (Fig. 1).
Effect of RCMV infection on acute rejection episodes
The mean serum creatinine levels of the allograft recipients
were measured twice a week to diagnose acute rejections, and the
diagnosis was made if there was an unexplained rise in serum
creatinine to > 200 mmol/liter. Additional CsA at a dose of 5
mg/kg/day was administered until the serum creatinine level fell
to < 200 mmol/liter.
Regardless of the highly standardized conditions, there was still
considerable interindividual variation in renal function during
rejection episodes and in the response to intensified immunosup-
pression. Because of the variability in the onset, intensity and
course of acute rejection episodes and their response to treat-
ment, we looked upon a single numerical parameter, the "Area
Under the Serum Creatinine versus Time Curve" (AUCcre), to
cover all these variables. We have shown [8] that the impact of
histopathological lesions in chronic rejection is related to the
frequency, and also to the intensity and length of acute rejections.
In the 1-week CsA treatment group, there was a slight increase
in the number of acute rejection episodes to 3.6 0.2 in
RCMV-infected allografts, compared to 2.6 0.3 in noninfected
renal allografts (P = 0,05; Fig. 2). There was also a statistically
nonsignificant increase in the AUCCrC covering the period from 3
to 12 weeks: 6245 752 per rat in the RCMV-infected renal
allografts compared to 5428 561 per rat in the noninfected renal
allografts (Fig. 3).
When the CsA treatment was extended to 12 weeks, no
rejection episodes were observed in the noninfected renal al-
lografts. In RCMV-infected allografts, the mean of rejection
episodes increased to 0.6 0.2 per rat (P < 0.05; Fig. 2). The
mean AUCCre covering the period from 3 to 12 weeks was
significantly higher (P < 0.05) in RCMV-infected rats (2992
742) when compared to noninfected allografts (733 348; Fig. 3).
Effect of RCMV infection on histological changes of kidney
allografts with 1-week CsA treatment
As shown in Table 3, noninfected kidney allografts with the
1-week CsA treatment developed histological changes character-
istic to chronic rejection 12 weeks after transplantation. In the
interstitium, a mild-to-moderate interstitial inflammation of
mononuclear cells occurred consisting of lymphocytic and mono-
cytic cell types. As determined by Unna Pappenheim staining,
24% of inflammatory cells represented pyroninophilic cells. In
addition, the inflammatory cell response was associated with a
mild fibrosis in the interstitium. In the glomeruli, the most striking
features were moderate mesangial matrix increase, mild capillary
basement membrane thickening, and mild sclerosis. Arteries and
arterioles of noninfected kidney allografts were affected by mod-
erate endothelial cell proliferation and mild obliteration. In
tubuli, moderate epithelial atrophy, mild capillary basement
membrane thickening and epithelial vacuolation were identified.
In RCMV-infected kidney allografts with the 1-week CsA
treatment, the extent of histological alterations was quite similar
to noninfected allografts with comparable immunosuppression
(Table 3). As compared to noninfected rats, the degree of
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Fig. 2. Effect of RCMV infection on episodes of acute rejections in kidney
allografts with one week CsA treatment (DA->WF, N = 7; DA->WF +
RCMV N = 5) and in kidney allografts with 12-week CsA treatment
(DA->WF, N = 5;DA->WF + RCMV N = 5).
interstitial inflammation, vascular wall pathology, and chronic
tubular changes did not significantly differ in RCM V-infected rats.
Only in the glomerular capillary basement membrane thickening
of RCMV-infected allografts was a statistically significant differ-
ence observed (P < 0.05) when compared to noninfected 1-week
CsA treated controls.
Effect of RCMV infection on the development of chronic rejection
in kidney allografis with continuous cyclosporine A treatment
In noninfected kidney allografts with the 12-week CsA treat-
ment hardly any histological changes attributable to chronic
rejection occurred. Only a mild glomerular mesangial matrix
increase and tubular epithelial vacuolation were observed (Table
3).
In RCMV-infected kidney allografts with the 12-week CsA
treatment, early changes of chronic rejection could be detected
(Table 3). In the interstitium, there was a significant increase in
the degree of interstitial inflammation with a strong pyronino-
philic component (P < 0.025). According to immunohistochem-
istry (Table 4), inflammatory cells represented helper T cells
Fig. 1. Photomicrographs demonstrating RCMV early and late antigen
expression in kidney allografts with 12-week CsA immunosuppression. (A) No
immunoreactivity was observed in spleen cells of noninfected rats (nega-
tive control). (B) Intense immunoreactivity was observed in spleen cells of
RCMV-infected rats (positive control). (C) No immunoreactivity was
observed in kidney allografts of noninfected rats. (D) Tubular epithelial
cells of kidney allografts in RCMV-infected rats showed focal RCMV
early and late antigen expression. [Original magnification X40; monoclo-
nal antibodies against early (monoclonal #8) and late (monoclonal #35)
antigens of RCMV revealed by the indirect three-layer immunoperoxidase
technique.]
Fig. 3. Effect of RCMV0n AUC (weeks 3 through 12) in kidney allografts
with 1-week CsA treatment (DA->WF, N = 7; DA->WF + RCMV N = 5)
and in kidney allografts with 12-week CsA treatment (DA->WF, N = 5;
DA->WF + RCMF N = 5). Data are mean SEM, statistical analysis
between the groups by nonparametric Mann-Whitney U-test.
(W3/25), activated macrophages (ED2, ED3), cytotoxic T cells
(0X8), and NK cells (3.2.3) in that order of magnitude. However,
there was no difference in immune activation, as determined by
MHC class II, IL-2 receptor, ICAM-1, and VCAM-1 expression
on the interstitial inflammatory infiltrate.
In the glomeruli, RCMV infection was associated with en-
hanced mesangial matrix increase (P < 0.05) and capillary base-
ment membrane thickening (P < 0.01) when compared to nonin-
fected controls. Mild glomerular inflammation consisting of
helper T and cytotoxic T cells (P < 0.05) was somewhat more
characteristic to RCMV (Table 4). No difference in glomerular
mesangial cell or parietal epithelial ICAM-1 expression nor in
glomerular sclerosis between noninfected and RCMV-infected
grafts was seen (Table 3).
In arteries of RCMV-infected kidney allografts under continu-
ous CsA treatment, mild endothelial cell swelling (P < 0.025) and
endothelial proliferation (P = 0.05) was observed. Most impor-
tantly, RCMV infection significantly accelerated the development
of intimal proliferation of arteries and arterioles (P < 0.025) as
compared to noninfected controls. No perivascular or vessel wall
inflammation was detected. These vascular wall changes of
RCM V-infected allografts, attributable to chronic kidney allograft
rejection, that is, allograft arteriosclerosis, were associated with
significantly increased ICAM-1 expression on the endothelium of
arteries, arterioles and capillaries (Table 5 and Fig. 4; P < 0.05).
With continuous CsA treatment, tubular histological changes
were mild both in noninfected and RCMV-infected rats (Table 3).
In RCM V-infected allografts, slight epithelial atrophy (P < 0.025)
was recorded, whereas there was no statistical difference in
tubular epithelial vacuolation or in capillary basement membrane
thickening between the noninfected and RCMV-infected kidney
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Table 3. Effect of RCMV infection on histological changes of rat kidney allografts with different CsA treatment
1 week CsA treatment 12 weeks CsA treatment
DA->WF DA->WF + RCMV P DA->WF DA->WF + RCMV P
(N = 7) (N = 5) value (N = 5) (N = 5) value
Interstitium
Inflammation 1.5 0.1 1.6 0.1 0.613 0.1 0.1 0.9 0.2 0.012
Pyroninophilic cells % 24 3 19 5 0.705 0.0 0.0 18 7
Fibrosis 1.2 0.2 1.3 0.2 0.876 0.3 0.3 0.9 0.2
0.019
0.060
Glomeruli
Mesangial matrix increase 1.6 0.2 2.0 0.2 0.148 0.4 0.1 0.9 0.2
Capillary basement membrane thickening 0.6 0.2 1.4 0.1 0.036 0.0 0.0 0.7 0.1
Sclerosis 0.4 0.2 1.0 0.4 0.128 0.0 0.0 0.3 0.2
0.045
0.005
0.136
Vessels
Endothelial swelling 0.0 0.0 0.3 0.3 0.206 0.0 0.0 0.6 0.2
Endothelial proliferation 0.0 0.0 0.3 0.3 0.206 0.0 0.0 0.5 0.2
Intimal proliferation 1.8 0.3 2.2 0.3 0.296 0.0 0.0 0.6 0.2
Inflammation 0.0 0.0 0.0 0.0 1.000 0.0 0.0 0.0 0.0
0.017
0.053
0.018
1.000
Sclerosis 0.0 0.0 0.2 0.1 0.062 0.0 0.0 0.5 0.3 0.053
Obliteration 0.8 0.2 1.5 0.5 0.176 0.0 0.0 0.5 0.3 0.053
Tubuli
Epithelial vacuolation 0.3 0.5 0.2 0.2 0.842 0.5 0.2 0.1 0.1
Epithelial atrophy 1.6 0.2 1.3 0.2 0.318 0.0 0.0 0.6 0.2
Capillary basement membrane thickening 0.7 0.2 0.6 0.2 0.629 0.0 0.0 0.2 0.2
0.065
0.017
0.317
Data are mean SEM. All specimens were scored blindly from 0 to 3 (0, normal; 1, mild; 2, moderate; 3, severe changes) by two investigato
the score was determined after a consensus had been reached. Statisical analysis between groups by the nonparametric Mann-Whitney U-test.
rs and
allografts. However, RCMV infection was significantly associated
with enhanced ICAM-1 expression in tubular epithelial cells
compared to controls (Fig. 4; P < 0.01).
Effect of RCMV infection on the Chronic Allograft Damage Index
We have previously demonstreted that the histological alter-
ations of chronic rejection in man may be quantitated as a number
by the CADI [251. To quantitate the intensity of chronic rejection,
we used the quantitative histological CADI and end-point trans-
plant function (serum creatinine).
The final four-week mean serum creatinine levels of 12-week
CsA treatment are given in Figure 5 where the mean serum
creatinine and the standard error are depicted. Serum creatinine
values were significantly higher in the allogeneic 12-week CsA-
treated RCMV-infected group (148 16, 179 20, 141 13 and
154 29 at 9, 10, 11 and 12 weeks, respectively) for the last four
weeks before sacrifice when compared to allograft recipients in
the 12-week CsA-treated noninfected group, none of which had
chronic rejection at sacrifice (100 8, 102 7, 93 7 and 85
6 at 9, 10, 11 and 12 weeks, respectively). The same relationship
was also seen in quantitative histopathology. The CADI score was
4.3 0.8 in the allografts of the 12-week CsA-treated RCMV-
infected group (Fig. 6) compared to 0.80 0.4 in the allografts of
the 12 week CsA-treated noninfected group (P < 0.05).
However, in the 1-week CsA-treated groups, the mean serum
creatinine was quite similar in the noninfected and RCMV-
infected allografts during the post-transplant course and end-
point transplant function (not shown). There was a slight nonsig-
nificant increase in the CADI score in the RCMV-infected
allografts (9.4 0.5) compared to that of noninfected allografts
(7.8 0.6; Fig. 6).
Discussion
Prior clinical studies have revealed that CMV infection is a
significant risk factor for the development of graft failure and
death after renal transplantation [9]. It has been associated also
with acute rejection [26, 271 and glomerulopathy of kidney
allografts [28]. In other solid organ transplantation, a wealth of
clinical and experimental evidence supports the role of CMV in
the development of cardiac allograft arteriosclerosis [29] and
vanishing bile duct syndrome of liver transplants [30].
This study provides experimental evidence that RCMV infec-
tion is associated with acute and chronic kidney allograft rejection
in rats on continuous CsA treatment. First, the number of acute
rejection episodes in RCMV-infected kidney allografts, as judged
by serum creatinine levels of > 200 molIliter, was significantly
up-regulated compared to similarly immunosuppressed nonin-
fected renal transplants. Second, the duration of each rejection
episode (in days), the level of elevation in serum creatinine over
normal values (in mmol/liter) and the efficacy of treatment, which
may all be quantitated by AUCCre, were significantly stronger in
RCMV-infected than the noninfected renal allografts. Third,
RCMV infection almost doubled the values of end-stage serum
creatinine, and fourth, there was a clear correlation between
RCMV infection and accelerated chronic allograft damage index
(CADI). In particular, RCMV infection was linked with the
following histological parameters attributable to chronic kidney
allograft rejection: interstitial inflammation, mesangial matrix
increase and capillary basement membrane thickening of glomer-
uli, endothelial cell swelling and intimal proliferation of arteries,
and epithelial atrophy of tubuli.
However, if CsA treatment was discontinued one week after
transplantation, no clear difference between noninfected and
RCM V-infected kidney allografts could be observed. We consider
this to be due to the very strong immunological injury per se
against the allograft. Thus, the immunologic changes accompany-
ing discontinuation of CsA are so profound as to render addi-
tional effects of CMV infection. It should also be noted that the
changes occurring in the CMV-infected rats receiving continuous
CsA are significantly less severe than in the two 1-week groups.
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Table 4. Effect of RCMV infection on inflammation of kidney
allografts under the 12-week treatment of CsA
12 weeks CsA treatment
DA - >WF
DA->WF +RCMV P
(N = 5) (N = 5) value
Cytotoxic T cells (0X8)
Interstitium 0.5 0 1.1 0.2 0.05
Glomeruli 0 0 0.3 0.1 0.05
Vessels 0 0 0 0 1.00
Tubuli 0 0 0.2 0.1 0.10
Helper T cells (W3/25)
Interstitium 1.4 0.2 2.8 0.2 0.01
Glomeruli 0.1 0.4 0.7 0.2 0.05
Vessels 0 0 0.1 0.1 0.20
Tubuli 0 0 0.5 0.2 0.06
Monocytes/macrophages
(ED1)
Interstitium 1.4 0.3 1.8 0.1 0.30
Glomeruli 0.2 0.1 0.4 0.1 0.20
Vessels 0 0 0 0 1.00
Tubuli 0 0 0.3 0.1 0.05
Macrophages/dendritic
cells (ED2)
Interstitium 0.7 0.2 1.3 0.2 0.05
Glomeruli 0.1 0.1 0.1 0.1 1.00
Vessels 0 0 0 0 1.00
Tubuli 0 0 0 0 1.00
Macrophages (ED3)
Interstitium 0.4 0.2 1.5 0.2 0.01
Glomeruli 0 0 0.2 0.1 0.10
Vessels 0 0 0 0 1.00
Tubuli 0 0 0.1 0.1 0.30
NK cells (3.2.3)
Interstitium 0.4 0.2 0.9 0.2 0.10
Glomeruli 0 0 0.2 0.1 0.10
Vessels 0 0 0 0 1.00
Tubulj 0 0 0 0 1.00
Data are mean SEM. All specimens were scored blindly from 0 to 3 (0,
normal; 1, mild; 2, moderate; 3, severe changes) by two investigators and
the score was determined after a consensus had been reached. Statistical
analysis between groups by the nonparametric Mann-Whiney U-test.
The natural history of RCMV infection has been described [22].
In this study, higher amounts of infectious RCMV could be
recovered from the salivary glands of rats receiving continuous
CsA treatment. In addition, immunohistochemistry revealed early
and late RCMV antigen expression in scattered interstitial inflam-
matory cells seven days after RCMV infection as well as in tubular
epithelial cells at three months postoperatively in rats receiving
continuous CsA treatment. Inflammatory cell infiltrates around
tubuli and vascular structures did not express RCMV antigens,
but enhanced tubular inflammation of ED1 positive cells was
recorded concurrently with tubular RCMV antigen expression at
three months. No antigen expression could be detected in kidney
allografts whose CsA treatment was discontinued after the first
week. These results support previous observations that immuno-
suppression, particularly the type that suppresses cellular immu-
nity, such as CsA, is a prerequisite for active and prolonged
RCMV infection by suppressing MHC-restricted, virus-specific
cytotoxic T cells; consequently, higher virus titers are reached in
various organs [31]. In our model, the follow-up ended at three
months, but we anticipate that the antigen expression in the
immunosuppressed allografts would also persist thereafter.
Table 5. Effect of RCMV infection on MHC class II, IL-2R, ICAM-1,
and VCAM-1 expression of kidney allografts under 12 week treatment
of CsA
12 weeks CsA treatment
DA — >WF
DA->WF +RCMV P(N 5) (N = 5) value
MHC class II
Interstitial cells 2.1 0.4 2.4 0.4 0.40
Glomerular mesangial cells 0 0 0 0 1.00
Glomerular parietal epithelium 0 0 0 0 1.00
Vascular endothelium 0 0 0 0 1.00
Tubular cells 0 0 0 0 1.00
IL-2R (CD 25)
Interstitial cells 0 0 0 0 0.30
ICAM-1 (CD 54)
Interstitial cells 1.8 0.3 2.4 0.2 0.10
Glomerular mesangial cells 1.2 0.2 1.6 0.2 0.20
Glomerular parietal epithelium 1.2 0.2 1.6 0.2 0.20
Vascular endothelium 0.6 0.2 1.8 0.2 0.05
Tubular cells 0.2 0.2 1.4 0.4 0.01
VCAM-1 (CD 106)
Dendritic cells 1.6 0.2 2.0 0.3 0.30
Glomerular mesangial cells 0 0 0 0 0.30
Glomerular parietal epithelium 1.2 0.2 1.1 0.1 0.90
Vascular endothelium 1.3 0.3 1.7 0.2 0.30
Tubular cells 0 0 0 0 1.00
Data are mean SEM. All specimens were scored blindly from 0 to 3 (0,
normal; 1, mild; 2, moderate; 3, severe changes) by two investigators and
the score was determined after a consensus had been reached. Statistical
analysis between groups by the nonparametric Mann-Whitney U-test.
Therefore, like human CMV, RCMV is poorly pathogenic but the
virus may cause an ongoing and more severe disease in an
immunocompromised host.
It has been demonstrated that CMV is able to infect various
kidney cell types, and it has been suggested that glomerular
structures might be a particular target for the virus [32]. Ustinov
et al found that human kidney mesangial cells, glomerular epithe-
hal cells, endothelial cells and tubular epithelial cells can be
infected by human CMV in vitro [33]. Studies on fetal tissues have
shown that CMV can replicate in mesangial cells [34] as well as in
glomerular and tubular epithelial cells [35] in vitro. CMV is also
able to infect endothelial cells [36 —381, and it has been recovered
from kidney vascular structures in biopsy and autopsy material
[39—41]. Earlier studies with RCMV found some RCMV early
and late antigen immunoreactive cells in the capillaries of glomer-
uli and in the capsule of the kidney both in unmodified and
X-irradiated rats [22].
It has been shown that acute rejection is a risk factor for graft
loss [4—7]. A recent study identified two new risk factors for
chronic rejection in human renal transplant recipients: infection
and a CsA dosage of < 5 mg/kg/day at one year [3]. On the other
hand, some studies have associated CMV infection with both
acute and chronic rejection [27, 29, 301 while others have not [23,
42, 43]. The present study provides experimental evidence that
RCMV infection increases the number of acute rejection episodes
in kidney allografts under continued CsA immunosuppression, as
judged by serum creatinine over 200 tmol/1iter. This suggests that
RCVM infection is linked with an early inflammatory response in
the graft, which may persist at low levels and produce inflamma-
tory cytokines, which would possibly induce continuous immuno-
logical injury in the graft and lead to accelerated changes of
•'k' '
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Fig. 4. ICAM-1 expression in noninfected kidney
allograft with continuous CsA immunosuppression.
(A) Note that the tubular cells and arteriolar
endothelium stain negative for ICAM-1. Effect
of RCMV infection on ICAM-1 expression in a
kidney allograft with continuous CsA treatment.
Note the strong (B) tubular epithelial cell and
(C) arteriolar endothelial cell ICAM-1
expression. (Original magnification X40, a
mouse IgGi monoclonal antibody to rat ICAM-
1 and a three-layer immunoperoxidase
technique.)
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chronic rejection. This is supported by the present finding that
ICAM-l expression was particularly intense in the interstitial
inflammatory infiltrates themselves. Furthermore, in CMV-in-
fected allografts receiving continuous CsA immunosuppression,
enhancement of glomerular and tubular inflammation occurred.
The cytokines that these inflammatory cells produce, particularly
macrophages, may up-regulate in situ ICAM-1 and possibly other
adhesion molecules, which was the case in this study with in-
creased ICAM-1 expression in vascular endothelial cells and
tubular cells in CMV infected allografts. This ICAM-1 up-
regulation may contribute to the increased chronic changes
observed in RCMV infected allografts by enhancing the anti-
allograft responses towards these structures.
Several studies have indicated the proinflammatory role of
CMV infection. CMV induces the expression of IgU F receptors
on the virus infected cells [44], and thus allows interaction with
granulocytes [45]. The immediate early gene of HCMV is able to
code for a protein that has sequence homology and immunologic
cross-reactivity with the HLA-DR 13-chain [46], and there is
evidence that CMV directly, in the absence of IFN-y, induces
class II molecule expression on rat heart capillary endothelia [471.
However, opposite results exist [481. In our study, CMV infection
was not associated with class II up-regulation, despite the en-
hancement of interstitial inflammation. This may be due to the
relatively tight CsA immunosuppression known to block especially
the IL-2 IFN-y pathway.
In addition, CMV encodes a glycoprotein homologous with the
heavy chain of MHC class I antigens that has the ability to bind
the light chain of MHC class I molecule [491. CMV up-regulates
MHC class I and ICAM-1 expression as a direct effect of the virus
on CM V-infected proximal tubular epithelial cells [50], and
possibly up-regulates MHC class II expression in kidney allografts
Fig. 6. Effect of RCMJ/ infection on chronic allograft damage index (CAD!)
in kidney allograjis with 1-week CsA treatment (DA-> WF, N = 7; DA-
>WF+RCMV N = 5) and in kidney allografts with 12-week CsA treatment(DA->WF, N = 5; DA->WF+RCMV, N = 5). Data are mean SEM,
statistical analysis between the groups by nonparametric Mann-Whitney
U-test.
via IFN-y released by activated T cells [26]. In this study, the
immunosuppressive dose of CsA used was relatively high. Thus,
CsA with a nearly exclusive effect on the transcription of immune
cytokines would inhibit the effect of CMV on class II up-
regulation. CMV may also regulate smooth muscle cell MHC
class I expression, and hence might alter the immunogenicity of
these cells [51]. Moreover, induction of VCAM-1 on heart
capillary endothelial cells has been found during CMV infection
[521.
CMV infection may also regulate cytokine and growth factor
production. Human CMV infection up-regulates IL-i-p gene
expression, leading to increased production of IL-i by monocyte!
macrophage cell lineage [53]. However, also opposite results exist
[54]. Studies in AIDS patients with CMV-induced severe colitis
have shown that CMV induces production of TNF-a by mono-
cytes and mucosal macrophages [55]. In addition, CMV immedi-
ate early genes up-regulate the expression of IL-2 and IL-2
receptor genes [56]. On the other hand, CMV immediate early
genes prevent the inhibitory effect of CsA on IL-2 gene transcrip-
tion in vitro, and thus possibly enhance the immune responses
against the grafted organ [57]. In addition, we have demonstrated
that RCMV infection enhances the mRNA expression of platelet-
derived growth factor-BB and transforming growth factor-p1 in
rat aortic allografts associated with RCMV-induced early inflam-
matory response in the vascular wall [58].
To conclude, our results provide experimental evidence that
RCMV infection is associated with increased acute rejection rate
as well as enhanced chronic allograft changes in rat kidney
transplant recipients under continuous CsA immunosuppression.
In the molecular level these RCMV-induced chronic changes are
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Fig. 5. Effect of RCMV infection on the level of serum creatinine (weeks 9
through 12) in kidney allografts with 12-week CsA treatment (E', DA->WF,
N = 5; DA->WF+RCMV N = 5). Data are mean SEM, statistical
analysis between the groups by nonparametric Mann-Whitney U-test.
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linked with increased vascular endothelial and tubular epithelial
ICAM-1 expression. Supporting the concept that CMV is able to
infect various kidney cell types, we found early and late RCMV
antigen expression in the cortical area of the renal transplant, in
tubular epithelial cells as well as in interstitial inflammatory cells.
Taken together, we postulate that RCVM infection is linked with
an early inflammatory response in the graft that may persist at low
levels and produce inflammatory cytokines, possibly inducing a
continuous immunological injury in the graft that could lead to the
accelerated changes of chronic rejection.
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